Zim Laboratories Ltd

Company Profile

Zim Laboratories Ltd had its IPO on under the ticker symbol ZIMLAB.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Zim Laboratories Ltd has a staff strength of 505 employees.

Stock update

Shares of Zim Laboratories Ltd opened at ₹120.15 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹115.4 - ₹124.5, and closed at ₹118.9.

This is a -2.22% slip from the previous day's closing price.

A total volume of 74,010 shares were traded at the close of the day’s session.

In the last one week, shares of Zim Laboratories Ltd have slipped by -7.36%.

Zim Laboratories Ltd's Key Ratios

Zim Laboratories Ltd has a market cap of ₹3.67 billion, indicating a price to book ratio of 2.7759 and a price to sales ratio of 1.4476.

In the last 12-months Zim Laboratories Ltd’s revenue was ₹3.98 billion with a gross profit of ₹1.67 billion and an EBITDA of ₹482.26 million. The EBITDA ratio measures Zim Laboratories Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zim Laboratories Ltd’s operating margin was 8.7% while its return on assets stood at 6.06% with a return of equity of 12.35%.

In Q3, Zim Laboratories Ltd’s quarterly earnings growth was a positive 61.3% while revenue growth was a positive 16.4%.

Zim Laboratories Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

15.3055

PEG

Its diluted EPS in the last 12-months stands at ₹4.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zim Laboratories Ltd’s profitability.

Zim Laboratories Ltd stock is trading at a EV to sales ratio of 1.4908 and a EV to EBITDA ratio of 10.5794. Its price to sales ratio in the trailing 12-months stood at 1.4476.

Zim Laboratories Ltd stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹3.44 billion

Total Liabilities

₹1.32 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Zim Laboratories Ltd ended 2024 with ₹3.44 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹3.44 billion while shareholder equity stood at ₹1.87 billion.

Zim Laboratories Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹1.32 billion in other current liabilities, 162419000.00 in common stock, ₹0 in retained earnings and ₹1.69 million in goodwill. Its cash balance stood at ₹74.63 million and cash and short-term investments were ₹137.44 million. The company’s total short-term debt was ₹438,816,000 while long-term debt stood at ₹0.

Zim Laboratories Ltd’s total current assets stands at ₹2.10 billion while long-term investments were ₹0 and short-term investments were ₹62.81 million. Its net receivables were ₹0 compared to accounts payable of ₹633.08 million and inventory worth ₹723.26 million.

In 2024, Zim Laboratories Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Zim Laboratories Ltd paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹118.9

52-Week High

₹124.35

52-Week Low

₹68.05

Analyst Target Price

₹

Zim Laboratories Ltd stock is currently trading at ₹118.9 per share. It touched a 52-week high of ₹124.35 and a 52-week low of ₹124.35. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹122.38 and 200-day moving average was ₹120.92 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 8457.1% of the company’s stock are held by insiders while 0% are held by institutions.